BioAgilytix announced the acquisition of IPM Biotech, a German-based bioanalytical CRL with expertise in immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD). In addition to providing a site for BioAgilytix’s European headquarters, the acquisition integrates the IPM Biotech team’s specialized expertise in immune mediated diseases and disorders.

«BioAgilytix is currently a trusted partner to 21 of the top 25 global pharmaceutical and biotech companies – said Dr. Afshin Safavi, founder and chief scientific officer of BioAgilytix. – The addition of IPM’s deep scientific expertise and European presence will enable us to more easily support these customers, and new global clients, who have sites on both continents, particularly in Phase II and III trials».